ClinicalTrials.gg
Sign In

Histiocytosis, Langerhans-Cell clinical trials

The registry lists 81 studies for Histiocytosis, Langerhans-Cell across more than 10 countries. 23 are recruiting or about to start. 47 of them are mainly about Histiocytosis, Langerhans-Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Get an email when these change. Save the Histiocytosis, Langerhans-Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
22
Active, not recruiting
22
Recruiting
19
Status unknown
8
Terminated
4
Not yet recruiting
2

Phase

Phase 2
50
Phase 1
9
Phase 3
6
Phase 4
2

Where

United States
47
China
17
Puerto Rico
13
France
9
Canada
7
Australia
7

Who runs them

National Cancer Institute (NCI) (15) · Assistance Publique - Hôpitaux de Paris (6) · Masonic Cancer Center, University of Minnesota (4) · Memorial Sloan Kettering Cancer Center (3) · Dana-Farber Cancer Institute (3) · Peking Union Medical College Hospital (3) · West China Second University Hospital (3) · Anna Raciborska (3)

What is being tested here

Drugs under test in Histiocytosis, Langerhans-Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Luvometinib404
Cytarabine336
Trametinib215
Prednisone224
Thalidomide103
Mercaptopurine122
Dabrafenib112
Tovorafenib101
Cobimetinib101
Mirdametinib101

Drug classes tested here Antimetabolites 3 open · Corticosteroids 2 open · Tyrosine kinase inhibitors (TKIs) 1 open · Alkylating agents 8

Coming up

5phase 3 studies under way
11studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 19 Histiocytosis, Langerhans-Cell studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger. 13 (68%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (5%) take healthy volunteers.

Recruiting studies that take each age, of 19
AgeWomenMen
1013 (68%)13 (68%)
1817 (89%)17 (89%)
3011 (58%)11 (58%)
4010 (53%)10 (53%)
5010 (53%)10 (53%)
6510 (53%)10 (53%)
759 (47%)9 (47%)
859 (47%)9 (47%)

Across all 81 studies, recruiting or not: 59% stop at 75 or younger and 56% at 65; 70% take children; 0% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Histiocytosis, Langerhans-Cell studies take

Of 32 phase 2 interventional studies under Histiocytosis, Langerhans-Cell, half reached primary completion within 63 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 263 mo55–85 · 32 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 81. Browse all 81 → or search them.